Our Take
The trial data is real and clinically meaningful, but Dexcom is betting on Medicare coverage to unlock the commercial prize—and that decision has not landed yet.
Why it matters
Type 2 non-insulin users represent a much larger addressable market than insulin-dependent patients. If Medicare approves coverage, CGM shifts from niche tool to standard of care for millions.
Do this week
Diabetes care programs: monitor the Medicare decision timeline (expected by year-end) to plan patient education and supply chain setup before coverage begins.
Dexcom reports CGM benefit for type 2 non-insulin diabetes
Dexcom released data from a randomized controlled trial showing its G7 continuous glucose monitor improved blood sugar control in people with type 2 diabetes who do not use insulin. Over 26 weeks, G7 users saw a 0.9% reduction in HbA1c (a three-month average blood sugar marker) compared to a control group using standard self-monitoring (per company press release). Users also spent five additional hours per week in the target glucose range of 70–180 mg/dL. Dexcom states both findings are statistically and clinically significant. A full peer-reviewed publication is in preparation.
The trial timing aligns with Dexcom's pending Medicare coverage decision for type 2 non-insulin users. The company told investors it expects a Medicare ruling by the end of 2026. Separately, Dexcom announced an acquisition of Nutrisense, a dietary analysis and nutrition coaching platform, which the company plans to integrate into Stelo, its over-the-counter CGM for non-insulin users.
The real story is Medicare, not the RCT numbers
The trial results are solid, but they are not surprising. CGMs work best when users act on the data—a lesson proven in insulin-dependent populations years ago. The novel claim here is that non-insulin users (the majority of the ~37 million Americans with type 2 diabetes) also benefit from continuous monitoring, not fingerstick checks. That's clinically credible and economically significant.
What matters far more than the 0.9% HbA1c drop is whether Medicare will pay. Today, CGM reimbursement is restricted to insulin-requiring patients. If Medicare expands coverage to non-insulin users, the addressable market explodes and clinicians can prescribe CGM as standard of care rather than as a patient-funded experiment. That is the threshold question. The trial data is Dexcom's evidence for the FDA and Medicare—not a surprise to practitioners already using CGMs.
The Nutrisense acquisition signals Dexcom's bet that data alone is not enough. People need guidance on what to do with it. Layering nutrition coaching into Stelo is table stakes for winning non-insulin users who lack the insulin-adjustment literacy of type 1 patients.
Monitor Medicare's decision and prepare messaging
If you run a diabetes program or primary care clinic, the relevant deadline is Medicare's decision window (expected by year-end 2026). Use this time to: audit your current non-insulin patient population to estimate how many might benefit from CGM; review Dexcom's trial data and educational materials to prepare clinician scripts; and establish supply chain relationships before coverage activates. Early adopters will have supply and training advantages. Do not wait for the coverage decision to begin internal alignment on patient selection criteria and prior authorization workflows.